Cannabinoid research is a young field with a large body of literature, and not all of it is of the same quality. That mixture is behind almost every confusion: a headline that promises a lot usually comes from a small study in cells or animals that nobody has replicated yet.
Our role as a foundation is not to produce headlines but to help people read them.
Three questions before believing a result
Which model was studied? An experiment in cells or in mice says nothing directly about people. It is the first step in a long chain, and most molecules that work in the lab never show the same effect in clinical trials.
How many people, and for how long? A trial with few participants and a few weeks may detect a signal, but it cannot support firm conclusions about long-term effects. Sample size and duration are part of the result, not a technical detail.
Who funded the study, and what exactly was measured? Transparency about funding and a clearly defined primary outcome are what separate a data point from an interpretation.
What we can state as an organisation
- That evidence quality varies a lot by area: studying nausea or pain is not the same as studying cognition or mood disorders.
- That peer review is not an absolute guarantee, but it is a minimum filter.
- That context matters: dose, route of administration, preparation and the population studied all change the result.
A single data point is not a conclusion. And a conclusion is not a recommendation.
What we do with this
As an institutional starting point, the World Health Organization keeps a cannabis fact sheet summarising the state of the question from a health perspective; it is linked at the end of this article.
In every research story we publish we will apply the same standard: describe the study, point out its limits and link the original source so anyone can check it. When there is not enough evidence, we will say so as clearly as when there is.
The foundation does not sell products or treatments, and it will not recommend patterns of use. Its job is to give the public conversation about cannabinoids better materials.